Russia’s first experience with GLE/PIB for the treatment of HCV infection genotype 3A with cryoglobulinemia and concomitant HBV infection in a hemodialysis patient with CKD C5d awaiting kidney transplantation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents Russia’s first case of successful use of a 8-week therapy course using an original interferon-free combination of the third-generation NS3/4A protease inhibitor glecaprevir (GLE) and the second-generation NS5A-replication enzyme inhibitor pibrentasvir (PIB) in clinical practice to treat HCV infection genotype 3A with mixed cryoglobulinemia syndrome and concomitant HBV infection in a patient with chronic kidney disease C5d, who received chronic dialysis after elective bilateral nephrectomy for renal polycystosis and awaited donor kidney transplantation.

Full Text

Restricted Access

About the authors

D. Sulima

Acad. I.P. Pavlov First Saint Petersburg State Medical University; LLC «Exclusive» Medical Consulting Dental Center (EXCLUSIVE Multidisciplinary Medical Clinic)

MD Saint Petersburg

D. Lioznov

Acad. I.P. Pavlov First Saint Petersburg State Medical University; Research Institute of Influenza

Professor, MD Saint Petersburg

A. Yakovlev

Saint Petersburg State University; S.P. Botkin Clinical Infectious Diseases Hospital

Professor, MD Saint Petersburg

A. Smirnov

Acad. I.P. Pavlov First Saint Petersburg State Medical University

Professor, MD Saint Petersburg

V. Larionov

V.A. Almazov Medical Research Center

Email: vsevolod.larionov@gmail.com
Saint Petersburg

A. Batskikh

Acad. I.P. Pavlov First Saint Petersburg State Medical University

Saint Petersburg

V. Koryagin

LLC «Exclusive» Medical Consulting Dental Center (EXCLUSIVE Multidisciplinary Medical Clinic)

Candidate of Medical Sciences Saint Petersburg

O. Gorchakova

Acad. I.P. Pavlov First Saint Petersburg State Medical University

Candidate of Medical Sciences

E. Alekseeva

Acad. I.P. Pavlov First Saint Petersburg State Medical University

Candidate of Medical Sciences

E. Volkov

Saint Petersburg State University

Saint Petersburg

D. Popov

ZAO «Plasmofiltr»

Saint Petersburg

A. Vasilyev

Acad. I.P. Pavlov First Saint Petersburg State Medical University

Candidate of Medical Sciences Saint Petersburg

E. Kostereva

Acad. I.P. Pavlov First Saint Petersburg State Medical University

Saint Petersburg

R. Golubev

Acad. I.P. Pavlov First Saint Petersburg State Medical University

Saint Petersburg

References

  1. U.S. Food and Drug Administration. FDA approval of Mavyret for Hepatitis C, 2017. Available athttps://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm570038.htm [Acc. 05 Jan, 2019].
  2. Kwo P., Poordad F., Asatryan A. et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis // J. Hepatol. -2017; 67 (2): 263-71. https://doi.org/10.1016/jjhep.2017.03.039
  3. Puoti M., Foster G., Wang S. et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis // J. Hepatol. - 2018; 69 (2): 293-300. https://doi. org/10.1016/j.jhep.2018.03.007
  4. Forns X., Lee S., Valdes J. et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial // Lancet Infect. Dis. - 2017; 17 (10): 1062-8. https://doi.org/10.1016/S1473-3099(17)30496-6
  5. Zeuzem S., Foster G., Wang S. et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection // N. Engl. J. Med. - 2018; 378 (4): 35469. doi: 10.1056/NEJMoa1702417.
  6. Poordad F., Pol S., Asatryan A. et al. Glecaprevir/pibrentasvir in patients with HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure // Hepatology. - 2018; 67 (4): 1253-60. doi: 10.1002/hep.29671.
  7. Wyles D., Poordad F., Wang S. et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial // Hepatology. - 2018; 67 (2): 514-23. doi: 10.1002/hep.29541.
  8. Toyoda H., Chayama K., Suzuki F. et al. Efficacy and safety of glecaprevir/ pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection // Hepatology. - 2018; 67 (2): 505-13. doi: 10.1002/hep.29510.
  9. Asselah T., Kowdley K., Zadeikis N. et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 weeks in patients with Hepatitis C Virus genotype 2, 4, 5, or 6 infection without cirrhosis // Clin. Gastroenterol. Hepatol. - 2018; 16 (3): 417-26. doi: 10.1016/j.cgh.2017.09.027.
  10. Abutaleb A., Kottilil S., Wilson E. et al. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy // Hepatol. Int. - 2018; 12 (3): 214-22. doi: 10.1007/s12072-018-9873-y.
  11. Kumada H., Watanabe T., Suzuki F. et al. Efficacy and safety of glecaprevir/ pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection // J. Gastroenterol. -.2018; 53 (4): 566-75. doi: 10.1007/s00535-017-1396-0.
  12. Gane E., Lawitz E., Pugatch D. et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment // N. Engl. J. Med. - 2017; 377 (15): 1448-55. doi: 10.1056/NEJMoa1704053.
  13. Chute D., Chung R., Sise M. et al. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient // Kidney Int. - 2018; 93 (3): 560-7. doi: 10.1016/j.kint.2017.10.024.
  14. Reau N., Kwo P., Rhee S. et al. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection // J. Hepatol. - 2017; 66 (1): 90-3. https://doi.org/10.1016/ S0168-8278(17)30444-0.
  15. Kosloski M., Zhao W., Marbury T. et al. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects // Antimicrob. Agents Chemother. - 2018; 62 (3): 10e01990-17. doi: 10.1128/AAC.01990-17.
  16. Al-Rabadi L., Box T., Singhania G. Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates // Hemodial. Int. - 2018; 22 (1): 45-52. doi: 10.1111/hdi.12656.
  17. RxAbbVie U.S. Prescribing Information. Highlights of Prescribing Information (glecaprevir and pibrentasvir), 2018. Available at http://www.rxabbvie. com/pdf/mavyret_pi.pdf [Acc. 05 Jan, 2019].
  18. US Food and Drug Administration. FDA drug safety communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C, 2016. Available at https://www.fda.gov/Drugs/ DrugSafety/ucm522932.htm [Acc. 05 Jan, 2019].
  19. Resat Ozaras, Bilkul Mere, Fehmi Tabak. Occult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals // Clinical Gastroenterology and Hepatology. - 2017; 15 (4): 605. DOI: 10.1016/j. cgh.2016.11.030.
  20. Wang C., Ji D., Chen J. et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents // Clin. Gastroenterol. Hepatol. - 2017; 15 (1): 132-6. doi: 10.1016/j.cgh.2016.06.023.
  21. Mücke M., Backus L., Mücke V. et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis // Lancet Gastroenterol. Hepatol. - 2018; 3 (3): 172-80. DOI: 10.1016/ S2468-1253(18)30002-5.
  22. Pockros P. Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection // Gastroenterol. Hepatol. - 2017; 13 (9): 536-40.
  23. Holmes J., Yu M., Chung R. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals // Expert Opin. Drug Safety. - 2017; 16 (6): 651-72. doi: 10.1080/14740338.2017.1325869.
  24. RxAbbVie U.S. Prescribing Information. Patient Information MAVYRET, 2017. Available at https://www.rxabbvie.com/pdf/mavyret_PIL.pdf [Acc. 05 Jan, 2019].
  25. Belperio P., Shahoumian T., Mole L. et al. Evaluation of Hepatitis B Reactivation Among 62, 920 Veterans Treated With Oral Hepatitis C Antivirals // Hepatology. - 2017; 66 (1): 27-36. doi: 10.1002/hep.29135.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies